IP Library Granted Patent US 7,131,994
Granted Patent B2
US 7,131,994 · App. 10/793,976 · Granted Nov 7, 2006

Muscle-based grafts/implants

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,131,994
App. No.
10/793,976
Granted
Nov 7, 2006
Kind
B2
Abstract

The present invention is directed to a composition comprising a matrix suitable for implantation in humans, comprising defatted, shredded, allogeneic human muscle tissue that has been combined with an aqueous carrier and dried in a predetermined shape. Also disclosed is a tissue graft or implant comprising a matrix suitable for implantation in humans, comprising defatted, shredded, allogeneic human muscle tissue that has been combined with an aqueous carrier and dried in a predetermined shape. The composition and/or tissue graft or implant of the invention is usable in combination with seeded cells, a tissue growth factor, and/or a chemotactic agent to attract a desired cell.

Claims (41)

1. A composition comprising a matrix suitable for implantation in humans, said matrix comprising a dried aqueous slurry of shredded, allogeneic human muscle tissue.

2. The composition of claim 1 , wherein said muscle tissue is striated muscle tissue.

3. The composition of claim 2 , wherein said striated muscle tissue is skeletal muscle.

4. The composition of claim 1 , wherein said shredded allogeneic human muscle tissue is also defatted.

5. The composition of claim 1 , wherein said shredded allogeneic human muscle tissue was also lyophilized prior to shredding.

6. The composition of claim 1 , further comprising a particulate component selected from the group consisting of demineralized bone matrix (DBM), mineralized bone matrix, cortical cancellous chips (CCC), crushed cancellous chips, tricalcium phosphate, hydroxyapatite, biphasic calcium phosphate and combinations thereof.

7. The composition of claim 6 , wherein the particulate component constitutes from 50% to 99% of the dry weight of the composition.

8. The composition of claim 7 , wherein the particulate component constitutes from 90% to 99% of the dry weight of the composition.

9. The composition of claim 1 , further comprising an amount effective for forming new bone of a bone morphogenic protein (BMP), a LIM mineralization protein, or RUNX-2 protein.

10. The composition of claim 9 , wherein said BMP is selected from the group consisting of BMP-2, BMP-4 and BMP-7.

11. The composition of claim 10 , wherein said BMP is BMP-2.

12. The composition of claim 11 , wherein said BMP-2 is a recombinant human BMP-2.

13. An implant suitable for implantation in humans comprising a matrix of defatted, shredded, allogeneic human muscle tissue that has been combined with an aqueous carrier and dried into a predetermined shape.

14. The implant of claim 13 , wherein said muscle tissue is striated muscle tissue.

15. The implant of claim 14 , wherein said striated muscle tissue is skeletal muscle.

16. The implant of claim 13 , wherein said shredded allogeneic human muscle tissue is also defatted.

17. The implant of claim 13 , wherein said shredded allogeneic human muscle tissue was also lyophilized prior to shredding.

18. The implant of claim 13 , further comprising a particulate component selected from the group consisting of demineralized bone matrix (DBM), mineralized bone matrix, cortical cancellous chips (CCC), crushed cancellous chips, tricalcium phosphate, hydroxyapatite, biphasic calcium phosphate and a combination thereof.

19. The implant of claim 18 , wherein the particulate component constitutes from 50% to 99% of the dry weight of the implant.

20. The implant of claim 19 , wherein the particulate component constitutes from 90% to 99% of the dry weight of the implant.

21. The implant of claim 13 , further comprising an amount effective for forming new bone of a bone morphogenic protein (BMP), a LIM mineralization protein, or RUNX-2 protein.

22. The implant of claim 21 , wherein said BMP is selected from the group consisting of BMP-2, BMP-4 and BMP-7.

23. The implant of claim 22 , wherein said BMP is BMP-2.

24. The implant of claim 23 , wherein said BMP-2 is a recombinant human BMP-2.

25. The implant of claim 13 , wherein said matrix of digested allogeneic human muscle comprises from about 1% to about 100% of the final weight of said implant.

26. The implant of claim 25 , wherein said matrix of digested allogeneic human muscle comprises from 25% to about 85% of the weight of said tissue implant.

27. The implant of claim 18 , wherein said particulate component is DBM.

28. The implant of claim 27 , wherein said DBM is uniformly distributed throughout the matrix.

29. The implant of claim 27 , wherein said DBM is layered within said matrix.

30. The implant of claim 18 , wherein said particulate component is CCC.

31. The implant of claim 30 , wherein said CCC is uniformly distributed throughout the matrix.

32. The implant of claim 30 , wherein said CCC is layered within said matrix.

33. The implant of claim 13 further comprising digested allogeneic human tendon.

34. A method for making an implantable tissue comprising the steps of:

i. removing the fat and soluble proteins from allogeneic or xenogeneic mammalian muscle tissue;

ii. lyophilizing the muscle tissue from step (i);

iii. shredding the lyophilized muscle tissue;

iv. mixing the shredded muscle tissue in an aqueous carrier to form a muscle tissue slurry having a viscosity within the range of 1 centistoke to 20,000 centistokes;

v. transferring the muscle tissue slurry to an appropriate shaped mold; and

vi. drying the slurry in the mold to form the tissue implant having the corresponding shape of said mold.

35. The method of claim 24 , wherein the tissue implant is a shaped sponge.

Assignments (12)
TERMINATION AND RELEASE OF SECURITY INTEREST IN PATENTS AND TRADEMARKS Recorded Sep 25, 2025
From: ARES CAPITAL CORPORATION
To: RTI SURGICAL INC. D/B/A EVERGEN
Reel/Frame 072938/0203 →
SECURITY INTEREST Recorded Jul 21, 2020
From: RTI SURGICAL, INC.; PIONEER SURGICAL TECHNOLOGY, INC.; TUTOGEN MEDICAL (UNITED STATES), INC.
To: ARES CAPITAL CORPORATION, AS SECURITY AGENT
Reel/Frame 053273/0665 →
RELEASE OF SECURITY INTEREST Recorded Jul 21, 2020
From: JPMORGAN CHASE BANK, N.A., AS ADMINISTRATIVE AGENT
To: RTI SURGICAL, INC.; PIONEER SURGICAL TECHNOLOGY, INC.; TUTOGEN MEDICAL, INC.
Reel/Frame 053260/0398 →
INTELLECTUAL PROPERTY ASSIGNMENT AGREEMENT Recorded Jul 20, 2020
From: SURGALIGN SPINE TECHNOLOGIES, INC. (FORMERLY KNOWN AS RTI SURGICAL, INC.)
To: RTI OEM, LLC
Reel/Frame 053259/0019 →
CHANGE OF NAME Recorded Jul 20, 2020
From: RTI OEM, LLC
To: RTI SURGICAL, INC.
Reel/Frame 053259/0146 →
CHANGE OF NAME Recorded Jul 20, 2020
From: RTI SURGICAL, INC.
To: SURGALIGN SPINE TECHNOLOGIES, INC.
Reel/Frame 053248/0432 →
RELEASE OF SECURITY INTEREST Recorded Jul 20, 2020
From: ARES CAPITAL CORPORATION, AS AGENT
To: RTI SURGICAL, INC.; PIONEER SURGICAL TECHNOLOGY, INC.; TUTOGEN MEDICAL, INC.; PARADIGM SPINE, LLC; FOURTH DIMENSION SPINE, LLC
Reel/Frame 053257/0652 →
SECURITY INTEREST Recorded Mar 8, 2019
From: RTI SURGICAL, INC.; PIONEER SURGICAL TECHNOLOGY, INC.; TUTOGEN MEDICAL, INC.; PARADIGM SPINE, LLC; FOURTH DIMENSION SPINE, LLC
To: ARES CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
Reel/Frame 048543/0505 →
RELEASE OF SECURITY INTEREST Recorded Jun 7, 2018
From: TD BANK, N.A., AS ADMINISTRATIVE AGENT
To: RTI SURGICAL, INC.
Reel/Frame 046327/0184 →
RELEASE OF SECURITY INTEREST Recorded Jun 7, 2018
From: TD BANK, N.A., AS ADMINISTRATIVE AGENT
To: RTI SURGICAL, INC.
Reel/Frame 046327/0864 →
SECURITY INTEREST Recorded Jun 6, 2018
From: RTI SURGICAL, INC.; PIONEER SURGICAL TECHNOLOGY, INC.; TUTOGEN MEDICAL, INC.
To: JPMORGAN CHASE BANK, N.A., AS THE ADMINISTRATIVE AGENT
Reel/Frame 046303/0926 →
SECURITY INTEREST Recorded Aug 20, 2017
From: RTI SURGICAL, INC.
To: TD BANK, N.A.
Reel/Frame 043608/0874 →